The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Most importantly, one phase III and one phase II randomised trial demonstrated a survival advantage when a combination of trastuzumab plus chemotherapy was compared with the same chemotherapy alone [9, 10].”
BackgroundUntangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 2×
“Its activity is subsequent to homo- or heterodimerisation with the other family members [2] (Figure 1).”
BackgroundStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“In contrast, in mice lacking the Fc receptor (FcR / ) much of the therapeutic effect of trastuzumab was lost, with only 29% tumour growth inhibition observed [22].”
BackgroundNagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 2×
“[33], who demonstrated that trastuzumab specifically inhibits PI3K signalling by reducing PTEN tyrosine phosphorylation and by increasing PTEN membrane localisation and phosphatase activity.”
BackgroundStructure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H.-S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,612
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Molina, M. A., Codony‐Servat, J., Albanell, J., Rojo, F., Arribas, J., & Baselga, J. M. (2001) · PubMed · Cited by 946
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 882
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873
Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793
Pauletti, G., Dandekar, S., Rong, H., Ramos, L., Peng, H., Seshadri, R., & Slamon, D. J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.21.3651 · Cited by 670
Hudziak, R. M., Schlessinger, J., & Ullrich, A. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.20.7159 · Cited by 625
Herceptin acts as an anti-angiogenic cocktail
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623
Nahta, R., Hung, M.-C., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3856 · Cited by 607
Nagy, P., Friedländer, E., Tanner, M., Kapanen, A. I., Carraway, K. L., Isola, J., & Jovin, T. M. (2005) · Cancer Research · doi:10.1158/0008-5472.473.65.2 · Cited by 523
Gennari, R., Menard, S., Fagnoni, F., Ponchio, L., Scelsi, M., Tagliabue, E., Castiglioni, F., Villani, L., Magalotti, C., Gibelli, N., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0225 · Cited by 516
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01518520 · Cited by 498
Austin, C. D., De Mazière, A. M., Pisacane, P. I., van Dijk, S. M., Eigenbrot, C., Sliwkowski, M. X., Klumperman, J., & Scheller, R. H. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-07-0591 · Cited by 496
Jacobs, T. W., Gown, A. M., Yaziji, H., Barnes, M. J., & Schnitt, S. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.1983 · Cited by 457
Herceptin: mechanisms of action and resistance
Nahta, R., & Esteva, F. J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.01.041 · Cited by 446
Press, M. F., Slamon, D. J., Flom, K. J., Park, J., Zhou, J.-Y., & Bernstein, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.094 · Cited by 391
Spector, N. L., Xia, W., Burris, H., Hurwitz, H., Dees, E. C., Dowlati, A., O'Neil, B., Overmoyer, B., Marcom, P. K., Blackwell, K. L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.157 · Cited by 362
Mass, R. D., Press, M. F., Anderson, S., Cobleigh, M. A., Vogel, C. L., Dybdal, N., Leiberman, G., & Slamon, D. J. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.n.026 · Cited by 359
Christianson, T. A., Doherty, J. K., Lin, Y.-J., Ramsey, E. E., Holmes, R. S., Keenan, E. J., & Clinton, G. M. (1998) · PubMed · Cited by 302
Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression
Tripathy, D., Slamon, D. J., Cobleigh, M., Arnold, A., Saleh, M., Mortimer, J. E., Murphy, M., & Stewart, S. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.557 · Cited by 280
Normanno, N., Campiglio, M., De Luca, A., Somenzi, G., Maiello, M., Ciardiello, F., Gianni, L., Salomon, D. S., & Menard, S. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf020 · Cited by 273
Xia, W., Gerard, C. M., Liu, L., Baudson, N. M., Ory, T. L., & Spector, N. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208774 · Cited by 258
Yen, L., You, X.-L., Al Moustafa, A.-E., Batist, G., Hynes, N. E., Mader, S., Meloche, S., & Alaoui-Jamali, M. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203685 · Cited by 230
Correction: IGF-IR/HER-2 Contributes to Trastuzumab Resistance
(2008) · Cancer Research · doi:10.1158/0008-5472.can-68-22-cor1 · Cited by 230
Cooley, S., Burns, L. J., Repka, T., & Miller, J. S. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00089-2 · Cited by 213
Diermeier, S., Horváth, G., Knuechel-Clarke, R., Hofstaedter, F., Szöllősi, J., & Brockhoff, G. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.12.008 · Cited by 179
Sarup, J. C., Johnson, R. M., King, K. L., FENDLY, B. M., Lipari, M. T., Napier, M. A., Ullrich, A., & Shepard, H. M. (1991) · PubMed · Cited by 164
Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling
Lane, H. A., Motoyama, A. B., Beuvink, I., & Hynes, N. E. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s21 · Cited by 148
Köstler, W. J., Schwab, B., Singer, C. F., Neumann, R., Rücklinger, E., Brodowicz, T., Tomek, S., Niedermayr, M., Hejna, M., Steger, G. G., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0385-3 · Cited by 143
TGFα expression impairs Trastuzumab-induced HER2 downregulation
Valabrega, G., Montemurro, F., Sarotto, I., Petrelli, A., Rubini, P., Tacchetti, C., Aglietta, M., Comoglio, P. M., & Giordano, S. (2005) · Oncogene · doi:10.1038/sj.onc.1208478 · Cited by 142
Self-citationFaltus, T., Yuan, J., Zimmer, B., Krämer, A., Loibl, S., Kaufmann, M., & Strebhardt, K. (2004) · Neoplasia · doi:10.1593/neo.04313 · Cited by 140
Gelmon, K. A., Mackey, J. R., Verma, S., Gertler, S. Z., Bangemann, N., Klimo, P., Schneeweiß, A., Bremer, K., Soulières, D., Tonkin, K. S., et al. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.010 · Cited by 127
Fornier, M. N., Seidman, A. D., Schwartz, M. K., Ghani, F., Thiel, R. P., Norton, L., & Hudis, C. A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi059 · Cited by 126
Montemurro, F., Donadio, M., Clavarezza, M., Redana, S., Jacomuzzi, M. E., Valabrega, G., Danese, S., Vietti-Ramus, G., Durando, A., Venturini, M., et al. (2006) · The Oncologist · doi:10.1634/theoncologist.11-4-318 · Cited by 123
Self-citationKlos, K. S., Zhou, X., Lee, S., Zhang, L., Yang, W., Nagata, Y., & Yu, D. (2003) · Cancer · doi:10.1002/cncr.11656 · Cited by 111
Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.
Repka, T. L., Chiorean, E. G., Gay, J., Herwig, K. E., Kohl, V., Yee, D., & Miller, J. S. (2003) · PubMed · Cited by 102
Warburton, C., Dragowska, W. H., Gelmon, K. A., Chia, S., Yan, H., Masin, D., Denyssevych, T., Wallis, A. E., & Bally, M. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0244 · Cited by 83
Nl, S., Blackwell, K., Hurley, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.502 · Cited by 79
Gancberg, D., Järvinen, T. A. H., Leo, A. D., Rouas, G., Cardoso, F., Paesmans, M., Verhest, A. P., Piccart, M. J., Isola, J. J., & Larsimont, D. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1016146130767 · Cited by 70
Trastuzumab-based combination therapy for breast cancer
Montemurro, F., Valabrega, G., & Aglietta, M. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.1.81 · Cited by 48
Self-citationBussolati, G., Montemurro, F., Righi, L., Donadio, M., Aglietta, M., & Sapino, A. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602507 · Cited by 30
Self-citationIs the gefitinib plus trastuzumab combination feasible in breast cancer patients?
Normanno, N., Campiglio, M., Perrone, F., Luca, A. D., & Ménard, S. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi325 · Cited by 11
Cited by
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
“It is therefore likely that a combination of mechanisms accounts for the therapeutic activity of trastuzumab, including inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway, inhibition of angiogenesis and inhibition of HER2 receptor cleavag”
BackgroundMonoclonal Antibodies in Cancer Therapy
Zahavi, D., & Weiner, L. (2020) · Antibodies · doi:10.3390/antib9030034 · Cited by 831
Bertoli, G., Cava, C., & Castiglioni, I. (2015) · Theranostics · doi:10.7150/thno.11543 · Cited by 815
Dougan, M., & Dranoff, G. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132544 · Cited by 607
Metadata
- Authors
- Valabrega, G., Montemurro, F., & Aglietta, M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2007-06
- Volume
- 18
- Issue
- 6
- Pages
- 977-984
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2143738177
- Cited by
- 626
- References
- 52
- FWCI
- 17.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.